Heartland Advisors Inc. Purchases 10,000 Shares of Haemonetics Corporation $HAE

Heartland Advisors Inc. grew its position in Haemonetics Corporation (NYSE:HAE) by 13.3% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 85,000 shares of the medical instruments supplier’s stock after purchasing an additional 10,000 shares during the quarter. Heartland Advisors Inc.’s holdings in Haemonetics were worth $4,791,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HAE. Kemnay Advisory Services Inc. acquired a new stake in shares of Haemonetics during the 4th quarter worth approximately $26,000. True Wealth Design LLC raised its position in Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 335 shares in the last quarter. Leonteq Securities AG bought a new stake in Haemonetics during the fourth quarter worth $30,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Haemonetics during the fourth quarter worth $34,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HAE. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Mizuho lifted their target price on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. lowered their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $77.97 on Monday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 38.60, a P/E/G ratio of 1.57 and a beta of 0.52. The company’s fifty day moving average is $70.49 and its 200 day moving average is $66.15.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 5.21 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.